K

Kura Oncology
D

KURA

10.830
USD
0.78
(7.76%)
Market Closed
Volume
141,648
EPS
-2
Div Yield
-
P/E
-5
Market Cap
842,181,413
OverviewSignalsIdeasNews
Related Instruments
    C
    COLM
    -1.150
    (-1.36%)
    83.590 USD
    G
    GPS
    0
    (0%)
    0.000000 USD
    LULU
    LULU
    -10.42
    (-3.15%)
    319.88 USD
    NKE
    NKE
    1.000
    (1.32%)
    77.38 USD
    P
    PVH
    -1.810
    (-1.74%)
    102.110 USD
    R
    RL
    -3.060
    (-1.45%)
    208.340 USD
    U
    UAA
    0.08000
    (0.81%)
    9.95000 USD
    U
    ULTA
    -17.73
    (-4.63%)
    365.12 USD
    V
    VFC
    -0.115
    (-0.57%)
    20.155 USD
    More
News

Title: Kura Oncology

Sector: Healthcare
Industry: Biotechnology
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operationof the group is carried through the United States.